Attorney General Dave Sunday announced that Pennsylvania will receive over $1 million as part of a $202 million multistate ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

Several of the events took place at ‘upscale restaurants’ in San Francisco, at costs of up to $163 per person, according to ...

Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

State attorneys general and federal prosecutors alleged Gilead Sciences illegally bankrolled lavish events for prescribers.

The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

Pharma giant Gilead Sciences agreed to pay hundreds of millions of dollars to state health insurance programs after admitting ...

Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...

(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...